

BOARD OF GOVERNORS Officers

President
Richard J. Kagan, M.D.

President-Elect

Samuel H. Doppelt, M.D. Secretary Duke Kasprisin, M.D. Treasurer Michael J. Jeffries Immediate Past President Michael J. Joyce, M.D. Members-at-Large Margery S. Moogk Diane Wilson Council Chairs Councilof Accredited Member Tissue Banks Linda Martin Jeffrey A. Sandler Musculoskeletal Council Richard A. Metz Reproductive Council Armand M. Karow, Ph.D. Skin Council Glenn Greenleaf

EXECUTIVE OFFICE Chief Executive Officer I? Robert Rigney, Jr., J.D. Executive Director Jeanne C. Mowe

Tissue Bank Council

Perry L. Lange

COMMITTEE CHAIRS

Accreditation Ellen Heck Awards James Forsell, Ph.D. Bylaws Ronald Plessinger Education Diane Munro Ethics Caroline Klam Finance Michael J. Jeffries Governmental Affairs Richard Russo International Affairs Glenn Greenleaf Membership Christopher Borton Nominating Michael J. Joyce, M.D. Program Nancy Dock, Ph.D. Public and Professional Relations Tina Trimble Standards and Procedures

Duke Kasprisin, M.D.

MedicalAdvisory

Charles Garrison, M.D.

American Association of Tissue Banks

The leader in support of qua&y, safety and availability of cells and tissue 24th Annual Meeting, September 9-12, 2000, Sheraton Bal Harbour, Florida

9714 '01 FEB -6 A9 53

January 31, 2001

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852

Ms. Wendy Taylor
Desk Officer for FDA
Office of Information and Regulatory Affairs
Office of Management and Budget
New Executive Office Building
725 17th Street,N W.
Washington, DC 20503

Re: REQUEST FOR EXTENSION OF COMMENT PERIOD

Current Good Tissue Practice for Manufactuers of Human Cellular and Tissue-Based Products; Inspection and Enforcement (21 CFR Part 1271)

Docket No. 97N-484P

Dear Madams/Sirs and Ms. Taylor:

I am writing on behalf of the American Association of Tissue Banks (AATB) to request a 60-day extension of the comment period on the information collection provisions in the above-caption proposed rule.

The Food and Drug Administration (FDA) published this proposed rule in the January 8, 2001, edition of the Federal *Register*. The proposed rule contains two comment periods: written comments on the proposed rule itself are due by May 8, but written comments on the information collection provisions in the proposed rule must be submitted by February 7. The AATB hereby requests a 60-day extension of the February 7 comment period to on or about April 2, 2001.

97N-4849

EXT

Dockets Management Branch (HFA-305)
Food and Drug Administration
Ms. Wendy Taylor
Office of Management and Budget
January 31, 2001
Page 2


The reason for this request is that comments on the information collection provisions in the proposed rule could not feasibly be submitted within the 30-day time period permitted. The proposed rule contains at least 12 separate requests for information. Most of the data needed to respond are not readily available, and thoughtful consideration and research are required in order to provide meaningful information. It has taken the Agency several years to craft this proposed rule. Sound public policy dictates that more than 30 days are necessary to respond to requests for information that the Agency itself has been unable to gather over several years.

I thank you for your time and immediate consideration of this request, If you have any questions, please do not hesitate to contact me. I look forward to hearing from you at your earliest possible convenience.

Sincerely

P. Robert Rigney بريال . Chief Executive Officer

PRRJr/dbn





Intillimination Intillicent Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852

20457-000i Inddhaladaddadhalladhalladdalladdall